A Personalized Approach to Leveraging Cellular Pathways Knowledge in the Treatment of Metastatic, Hormone-Receptor Positive, HER-2 Negative Breast Cancer
Sara Hurvitz, MD
Associate Professor of Medicine
David Geffen School of Medicine at UCLA
Director, Breast Cancer Clinical Research Program
Co- Director, Santa Monica – UCLA Outpatient Oncology Practice
Santa Monica, CA
This activity will cover the treatment of patients with hormone receptor positive, HER-2 negative breast cancer.
This CME initiative is designed to meet the educational needs of medical oncologists, surgeons, ONS nurses, and other healthcare providers involved in the treatment of patients with breast cancer.
After completing the CME activity, learners should be better able to:
- Describe the genetic alterations in cellular pathways that control cell cycle transition in hormone receptor-positive breast cancer
- Review the pharmacodynamics and pharmacokinetics of the CDK 4/6 inhibitors in hormone receptor-positive breast cancer
- Discuss the CDK 4/6 inhibitor clinical trial data for patients with HR+, HER-2 negative advanced or metastatic breast cancer
- Explain the monitoring and practical side effect management strategies for CDK 4/6 inhibitors
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
This CME activity was planned and produced in accordance with the ACCME Essentials.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NURSING CREDIT INFORMATION
This program would be beneficial for nurses involved in the long-term treatment and management of patients with psoriasis.
CNE ACCREDITATION STATEMENT
Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 1.0 contact hour(s) of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME)
Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
Dr. Hurvitz is a consultant for Amgen, Bayer, BI Pharma, Genentech, GSK, Lilly, Novartis, Pfizer, Roche, PUMA, Merrimack, Medivation, Dignitana, DBI Pharma, Bomarin, Cascadian, and Seattle Genetics. She has traveled for Lilly, Novartis, OBI Pharma, and Bayer.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
UMA/CCM Nurse Reviewer—Barbara L. O’Brien, RN, MSN, has no relevant financial relationships to disclose.
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, General Manager of Med Learning Group has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group has nothing to disclose.
Nina Oshiokpekhai, MS, PharmD, Medical Director for Med Learning Group has nothing to disclose.
Lisa Crenshaw, Senior Program Manager for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP of Accreditation and Outcomes for Med Learning Group has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During the course of this lecture, Dr. Hurvitz may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:
1. Read the CME/CNE information and faculty disclosures;
2. Participate in the live activity.
3. Submit the evaluation form to Med Learning Group.
You will then receive your certificate.
Med Learning Group makes every effort to develop CME activities that are science-based.
This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact: Med Learning Group at email@example.com.
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at: http://www.medlearninggroup.com/privacy-policy/
RELEASE DATE: February 21, 2018
EXPIRATION DATE: February 21, 2019
This educational activity provides training necessary for licensed attendees to maintain state licensing requirements. The tuition for this educational activity is subsidized in part by unrestricted educational grants, including for those attendees who have successfully completed the state licensing requirements for their respective fields. This subsidy is reflected in the registration fees for this activity.
Copyright © 2018 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.